ProMIS Neurosciences Identifies Third Novel Therapeutic Target for Alzheimer's Disease

ProMIS Neurosciences announced that, following the identification of its first two targets announced on November 12, 2015 and February 3, 2016, it has identified a third in a series of novel potential therapeutic targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer’s disease.
According to the news:

The Company applied its unique, proprietary discovery platform to identify this third novel, distinct target (epitope) on strains of misfolded Amyloid beta and is currently in the process of identifying and validating a series of potential targets. Misfolded, propagating strains of Amyloid beta are known to be neurotoxic and widely believed by the scientific community to play a key role in the development and progression of AD.

ProMIS CEO, Dr. Elliot Goldstein stated:

We are pleased to announce that we have initiated the validation process by starting to raise the specific monoclonal antibodies (“mabs”) against the multiple targets identified. The validation program is designed to select mabs for drug development that bind selectively and specifically to the neurotoxic, propagating strains of misfolded Amyloid beta.

Click here to view the full press release.